European annals of allergy and clinical immunology最新文献

{"title":"Reply to \"Adrenalin use in Kounis syndrome: a wellunknown entity\".","authors":"G Zisa","doi":"N/A","DOIUrl":"N/A","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":"57 1","pages":"43-44"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of asthma on severe food-induced allergic reactions: a systematic review and meta-analysis.","authors":"M B Cilona, G A Ramirez, C Asperti, A Ferlito, G Benanti, S Nannipieri, R M Abdul Hadi, C Capellini, L Dagna, M Cottini, M-R Yacoub","doi":"10.23822/EurAnnACI.1764-1489.351","DOIUrl":"10.23822/EurAnnACI.1764-1489.351","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Food allergy can range from mild to severe, life-threatening reactions with various symptoms and organ involvement. The impact of asthma on severe food-induced allergic reactions is not completely understood. In the hypothesis that asthma increases the risk of severe food-induced allergic reactions, the aim of this study is to compare the incidence of severe food-induced allergic reactions in patients with history of asthma compared with patients without history of asthma. <b>Methods.</b> We performed a systematic research on electronic databases, including PubMed, Scopus and Web of Science. Observational studies, studies reporting medical characteristics of patients diagnosed with food allergy and studies reporting medical history of patients with allergic reactions were included. The primary outcome was the incidence of severe food-induced allergic reactions in patients with history of asthma compared with patients without history of asthma. <b>Results.</b> Eight studies with a total of 90,367 patients met the inclusion criteria and were included, with a total population of 28,166 of patients with food allergy. The incidence of severe food-induced allergic reactions in patients with history of asthma compared with patients without history of asthma was increased (OR 1.28; 95%CI 1.03-1.59; p = 0.03; I2 = 59%). <b>Conclusions.</b> Individuals with both food allergy and asthma are at high risk of severe, potentially fatal allergic reactions. Healthcare professionals should prioritize prevention and management strategies for these subjects. Patients with asthma and food allergy are at increased risk of potentially fatal food-induced allergic reactions. Optimal management of both diseases is nec-essary to prevent potentially life-threatening events. <b>Study registration.</b> The protocol of this review was registered in PROSPERO (CRD42023448293).</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"4-11"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141450159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to \"Adrenalin use in Kounis syndrome: a wellunknown entity\".","authors":"G Zisa","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":"57 1","pages":"43-44"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between baseline IgE level and urticaria control at six months of omalizumab treatment in chronic urticaria.","authors":"G Tuncay, E Damadoglu, G Karakaya, A Fuat Kalyoncu","doi":"10.23822/EurAnnACI.1764-1489.379","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.379","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> There is limited data on the use of baseline IgE level as a predictor of omalizumab response in chronic urticaria (CU). The aim of the present study was to determine if baseline serum total IgE level is associated with response at six months of standard-dose omalizumab. <b>Methods.</b> The study was designed as a retrospective, single-center, cohort survey. This observational real-life study included CU patients receiving omalizumab from September 1, 2014, to July 31, 2022 at a tertiary care allergy center. The control of urticaria was determined by the urticaria control test in the sixth month. <b>Results.</b> A total of 159 patients were enrolled in the study. All patients had received standard-dose omalizumab for six months. At the end of the treatment period, 126 (80%) patients were under control. The median of baseline IgE level was similar in controlled and uncontrolled patients. The baseline D-dimer level and regular antihistamine use during omalizumab treatment use were significantly higher, and CU duration at baseline was shorter in the uncontrolled group (p = 0.03, p = 0.02, p = 0.003, respectively). ROC analysis revealed that CU duration at baseline was related to urticaria control (AUC:0.665, 95%CI [0.586-0.738]). <b>Conclusions.</b> The results of the present study showed that urticaria control at six months of omalizumab treatment in CU was not associated with baseline IgE level but was associated with CU duration at baseline. The shorter CU duration was associated with poorer urticaria control in the sixth month of omalizumab.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is gastrointestinal epithelial barrier dysfunction the only responsible for sensitization to food allergens?","authors":"R Asero, V Pravettoni, D Villalta, E Scala","doi":"10.23822/EurAnnACI.1764-1489.378","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.378","url":null,"abstract":"<p><strong>Summary: </strong>Epithelial barriers are crucial defenses against pathogens and allergens, and recent theories suggest that environmental factors may compromise them, leading to type 2 inflammation and conditions such as asthma, atopic dermatitis, food allergy, and rhinitis. While skin and respiratory barriers show clear dysfunctions in allergies, the role of the gut epithelium is less defined, particularly in view of its ability to absorb nutrients and maintain immune tolerance under normal conditions. Research indicates that gastrointestinal barrier integrity typically remains preserved in food allergies, allowing for the development of immune tolerance to ingested food antigens through mechanisms like Treg cells and IgA. Allergies to cow's milk or hen's egg proteins most often resolve with age, highlighting the gut's evolving role in allergen sensitization. Studies like the LEAP (Learning Early About Peanut Allergy) trial demonstrate the preventive benefits of early allergen exposure against peanut allergy, supporting the dual allergen exposure hypothesis. New allergens such as alpha-Gal and gibberellin-regulated proteins (GRP) reveal distinct sensitization pathways beyond traditional ingestion routes, implicating non-dietary sources in allergen introduction. Altogether, there is lack of evidence suggesting that the intestinal epithelium is disrupted in food allergy.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep breathing disorders in adolescents with asthma.","authors":"P Simão Coelho, G Martins-Dos-Santos, M Mikovic, F Carvalho, M Cardoso, S Serranho, S Santos, A Brito, P Carreiro-Martins, P Leiria-Pinto","doi":"10.23822/EurAnnACI.1764-1489.377","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.377","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Childhood asthma, a chronic inflammatory disease, is linked to sleep-breathing disorders (SBD). The vulnerability of asthmatic children to SBDs is well-established, yet limited research focuses on adolescents. This study addresses the research gap, exploring the frequency and risk factors of SBD in adolescents with asthma. <b>Methods.</b> A cross-sectional study was conducted among 98 adolescents (12-17 years) with asthma at a Lisbon healthcare facility. Comprehensive assessments, including sociodemographic data, medical history, lung function variables, and validated questionnaires for SBD risk (Pediatric Sleep Questionnaire), rhinitis control, and asthma control (Control of Allergic Rhinitis and Asthma Test and Asthma Control Test), were employed. <b>Results.</b> The study revealed a substantial frequency of SBD symptoms, with 25.5% of adolescents classified as high-risk based on the Pediatric Sleep Questionnaire. Significant associations were identified between high SBD risk and elevated body mass index (BMI), uncontrolled rhinitis, and uncontrolled asthma. Logistic regression analysis confirmed elevated BMI as a robust predictor of SBD risk, indicating a 5.9-fold increase compared to normal-weight counterparts. <b>Conclusions.</b> This study contributes valuable insights into the interplay between asthma and SBD in adolescents. The high prevalence of SBD symptoms, particularly among those with excess weight and uncontrolled respiratory symptoms, underscores the need for targeted preventive strategies. The identified risk factors, notably elevated BMI, provide clinicians with actionable information for intervention, emphasizing the importance of addressing modifiable factors associated with asthma and SBD in this specific population.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The added value of targeting airway hyperresponsiveness by blocking TSLP in the management of severe asthma.","authors":"A Vaghi, M B Bilò, F Bini, L Cecchi, C Micheletto, A Musarra","doi":"10.23822/EurAnnACI.1764-1489.376","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.376","url":null,"abstract":"<p><strong>Summary: </strong>Airways hyperresponsiveness (AHR) is a pathognomonic event of asthma in which the airways are reactive to various bronchoconstrictor stimuli at 'doses' that normally have no bronchoconstrictor effect in non-asthmatics. AHR is an objective measure of clinical efficacy, and the introduction of biologics revived interest as a marker of disease and its pathophysiologic mechanism. This article aims to discuss the mechanisms of AHR, focusing on the role of epithelial damage and TSLP production, and promote its correct assessment for the evaluation of patients with severe asthma, to predict the risk of exacerbations and outcomes, and the eligibility for treatment with an anti-TSLP agent. AHR is a complex trait of asthma, induced by the concurrence of many pathophysiological factors and related to different clinical manifestations. Recent evidence demonstrates the important role of airway epithelial damage and TSLP production in many of these events. A therapeutic response based on AHR control could be considered as a condition of disease remission and seems a promising new goal for the management of patients with severe asthma.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe chronic spontaneous urticaria responding and not responding to omalizumab: analysis of the prognostic value of known and novel in-vitro variables.","authors":"R Asero, P Calzari, S Ferrucci, M Lorini, V Carbonelli, S Stella, D Consonni, M Cugno","doi":"10.23822/EurAnnACI.1764-1489.375","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.375","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Chronic spontaneous urticaria (CSU) response to anti-IgE treatment can be rapid, late or absent. Recently, potential mechanisms of activation of mast cells alternative to FceRI, including mas-related G protein-coupled receptor X2 (MRGPRX2), activation of coagulation cascade, and activation of eosinophils have been described. We measured several potential in-vitro markers, including well-known MRGPRX2 activators, in sera of patients CSU both responding and not responding to omalizumab. <b>Methods.</b> D-dimer, substance P (SP), eosinophil cationic protein (ECP), soluble MRGPRX2, IgE anti-FceRI, IgE anti-FceRII, IgG anti-FceRI and IgG anti-FceRII were measured in 32 patients with severe CSU at baseline and one week after the start of omalizumab therapy, and in 20 healthy controls. <b>Results.</b> At baseline CSU patients showed significantly higher levels of D-dimer, IgE anti-FceRI, IgG anti-FceRI, and ECP (p < 0.001 in all cases), and significantly lower levels of soluble MRGPRX2 (p = 0.009) than controls. The two groups showed similar levels of IgG and IgE to FceRII and SP. One week after the first omalizumab administration there was a significant drop of IgE anti-FceRI (p < 0.001) and D-dimer (p = 0.028), in early responders. SP increased in all CSU patients (p < 0.001) irrespective of the final response to omalizumab. IgE anti-FceRI response at one week was associated with the final response to omalizumab (OR:0.12 [95%CI 0.01-1.06]). <b>Conclusions.</b> Severe CSU is associated with high plasma levels of several biomarkers including D-dimer, IgE anti-FceRI, IgG anti-FceRI and ECP and low levels of soluble MRGPRX2. IgE anti-FceRI response at one week may predict the final response to omalizumab.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabis sativa as a clinically relevant nsLTP allergen in the Mediterranean region: a case series exemplifying different possible routes of sensitization.","authors":"A Bennici, D Grixti Soler, G Marcassa, G E Senna, S Gangemi, D Villalta, P L Minciullo","doi":"10.23822/EurAnnACI.1764-1489.374","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.374","url":null,"abstract":"<p><strong>Summary: </strong>Cannabis is the most widely used drug worldwide sought for recreational and medicinal purposes. Cannabis allergy was first described 50 years ago but has become more frequently reported over the past decade due to a larger industrial and domestic cultivation, and an evolving legal status. However, it remains an infrequent cause of allergy in the Mediterranean European countries. We describe three clinical cases with primary sensitization to cannabis characterized by anaphylactic reactions. We hypothesize that in all three case reports, sensitization to Can s 3 nsLTP played a crucial role in the development of anaphylaxis, either directly following ingestion of hemp-containing food, or even indirectly through primary sensitization via involuntary exposure or occupation exposure to cannabis sativa.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of concentrations of multidirectional omega-3 fatty acids in inborn errors of immunity with predominantly antibody defects: a pilot study.","authors":"K Napiórkowska-Baran, B Szymczak, J Lubański, Z Bartuzi","doi":"10.23822/EurAnnACI.1764-1489.373","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.373","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b>Omega-3 fatty acids are involved in many processes in the human body. Their beneficial effects were documented mainly in relation to cardiovascular and immune systems. Patients with immunodeficiencies with predominantly antibody defects due to their reduced immunoglobulin levels should have factors adversely affecting the course of the disease eliminated. <b>Methods.</b> Nineteen primary immunodeficient patients with predominant antibody defects (out of which fourteen with CVID) and eighteen immunocompetent participants had their blood tested in order to determine the concentration of EPA, DHA and omega-3 index values. The Mann-Whitney U tests were used to determine statistical significance. <b>Results.</b> Immunodeficient participants, especially with CVID, overall tend to have a slightly lower mean concentration of omega-3 fatty acids such as DHA and in particular EPA (CVID: 0.86% ± 0.28% <i>vs</i> 1.06% ± 0.31%, p = 0.095) as compared with the control group and the differences were most evident among patients aged 30-39 (0.67 ± 0.16% <i>vs</i> 1.12 ± 0.12%, p = 0.025). 63% of patients with immunodeficiency had an omega-3 index value between 4-8, compared to 39% in the control group. 37% of participants with predominantly antibody defects had an omega-3 index value > 8% (29% of all CVID group) compared with 61% of the control group. None of the participants achieved a result of 4% or lower. People without immunodeficiency consumed products rich in omega-3 acids more often. <b>Conclusions.</b> These findings suggest that primary immunodeficient patients with predominantly antibody defects tend to have lower omega-3 index values, albeit not significantly and seem to have higher cardiovascular risk than the control group. Research has also shown that education is needed regarding the effects and necessity of consuming products rich in omega-3 fatty acids, especially in patients with immunodeficiency.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}